Please assess the completion status of the following clinical trial:

Trial Title: Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The child is a permanent resident of the study area and likely to remain a resident for the duration of the trial~* The child is 5 - 17 months of age at the time of first vaccination~* A parent or legally recognised guardian provides informed consent for the child to join the trial~Exclusion Criteria:~* The child is a transient resident in the study area~* The child is in care~* The age of the child is outside the stipulated range~* The child has a history of an adverse reaction to SP or AQ~* The child has a serious underlying illness, including known HIV infection, unless this is well controlled by treatment, or severe malnutrition (weight for age or mid arm circumference Z scores \< 3 SD)~* The child is known to have an immune deficiency disease or is receiving an immunosuppressive drug~* The child has previously received a malaria vaccine.~* The child is enrolled in another malaria intervention trial~* The parents or guardians do not provide informed consent

- Gender: ALL
- Minimum Age: 5 Months
- Maximum Age: 17 Months
- Healthy Volunteers: f

Study Arms:
- SMC with SP+AQ (Type: ACTIVE_COMPARATOR): Administration of RABIPUR® in Year 1 and Hepatitis A vaccine in Year 2 and 3, followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.
- RTS,S/AS01 (Type: ACTIVE_COMPARATOR): Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with placebo in Year 1,2 and 3.
- RTS,S/AS01 PLUS SMC with SP+AQ (Type: ACTIVE_COMPARATOR): Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).